<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801385</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000618003</org_study_id>
    <secondary_id>YONSEI-4-2008-0160</secondary_id>
    <nct_id>NCT00801385</nct_id>
  </id_info>
  <brief_title>Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy</brief_title>
  <official_title>A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung&#xD;
      cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib&#xD;
      works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has&#xD;
      not responded to chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the response rate of sorafenib tosylate in combination with erlotinib&#xD;
           hydrochloride in patients with stage IIIB-IV non-small cell lung cancer refractory to 1&#xD;
           or 2 prior chemotherapy regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the response duration in patients treated with this regimen.&#xD;
&#xD;
        -  To assess the disease control rate in patients treated with this regimen.&#xD;
&#xD;
        -  To assess the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  To assess the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  To assess the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  To analyze biomarkers, including evaluation of EGFR expression, mutational analysis of&#xD;
           EGFR and K-ras, and immunohistochemical analysis of EGFR downstream pathway&#xD;
           (phospho-EGFR, phospho-AKT, phospho-Erk, phospho-STAT3).&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice&#xD;
      daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Tissue samples are analyzed at the nucleic acid level for EGFR mutation (exon 18-21) and&#xD;
      K-ras mutation (exon 2), DNA mutations via PCR, presence of EGFR protein by IHC, and&#xD;
      downstream effectors of EGFR activation by IHC.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response based on RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration in patients with confirmed objective response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Advanced (stage IIIB-IV) or recurrent disease&#xD;
&#xD;
          -  Must have failed 1 or 2 prior chemotherapy regimens, including platinum-containing&#xD;
             regimen&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion &gt; 10 mm by spiral CT scan or &gt; 20 mm by&#xD;
             conventional CT scan&#xD;
&#xD;
               -  Previously irradiated lesions cannot be included as sites of measurable disease&#xD;
                  unless clear tumor progression has been documented in the lesions since the end&#xD;
                  of radiotherapy&#xD;
&#xD;
          -  No known or suspected brain metastases&#xD;
&#xD;
               -  Patients with clinical signs or symptoms that are suspicious of brain metastasis&#xD;
                  must have a pre-treatment CT scan or MRI of the brain&#xD;
&#xD;
               -  Patients with prior brain metastases are eligible provided they have completed&#xD;
                  their treatment for brain metastases, no longer require corticosteroids, and are&#xD;
                  asymptomatic&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC 4,000-12,000/μL&#xD;
&#xD;
          -  Neutrophil ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.0 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.0 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No active clinically serious infections&#xD;
&#xD;
          -  No prior or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study except cervical carcinoma in situ, treated basal&#xD;
             cell carcinoma, superficial bladder tumors (Ta, Tis and T1), or any cancer curatively&#xD;
             treated &gt; 5 years before study&#xD;
&#xD;
          -  Able to swallow oral medications&#xD;
&#xD;
          -  No substance abuse or medical, psychological, or social conditions that may interfere&#xD;
             with participation in the study or evaluation of the study results&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior anti-EGFR targeted therapy&#xD;
&#xD;
          -  At least 4 weeks since prior surgery&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
               -  No prior radiotherapy to the whole pelvis or chest or to ≥ 25% of the bone marrow&#xD;
&#xD;
          -  No other concurrent anticancer agents (e.g., chemotherapy or immunotherapy agents)&#xD;
             which might affect evaluation of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hang Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hang Kim, MD</last_name>
      <phone>82-2-2228-8131</phone>
      <email>kjhang@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>August 21, 2009</last_update_submitted>
  <last_update_submitted_qc>August 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

